Haw Wei Yann, Polak Marta E, McGuire Carolann, Erlewyn-Lajeunesse Michel, Ardern-Jones Michael R
Department of Dermatopharmacology, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Department of Paediatric Allergy & Immunology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Ann Allergy Asthma Immunol. 2016 Jul;117(1):61-6. doi: 10.1016/j.anai.2016.04.017. Epub 2016 May 21.
Previous reports have demonstrated the utility of T-cell proliferation and cytokine release assays as in vitro diagnostic tests for drug causation in drug hypersensitivity reactions (DHR). However, data from pediatric populations are scarce compared with data in adults.
To compare the lymphocyte proliferation assay (LPA) with combination cytokine assays in the pediatric population and to identify its potential use in the acute and postrecovery phases.
A total of 18 in vitro tests were undertaken ex vivo to compare drug-specific proliferation and cytokine release (interferon-γ [IFN-γ] and interleukin-4 [IL-4]). The study included 16 patients with DHR: 7 children tested in the acute phase, 7 tested after recovery, and 2 tested during both the acute and postrecovery phases.
The sensitivity of the LPA was better during the acute stage of DHR in children. Cytokine assays revealed a higher frequency of positive drug-specific responses compared with LPA in both the acute (LPA, 77.8%; IFN-γ, 88.9%; IL-4, 100%) and postrecovery phases (LPA, 33.3%; IFN-γ, 66.7%; IL-4, 66.7%). Combination cytokine assays (IFN-γ and IL-4) produced higher positive drug-specific responses in identifying culprit drugs compared with LPA in both the acute and postrecovery phases.
In vitro drug-induced T-cell proliferation and cytokine release assays are useful for identification of the causative drug in children with DHR. Cytokine assays (IFN-γ and IL-4) were better than LPA, but when combined, they offer even greater utility in the diagnosis of acute and postrecovery DHR. Cytokine detection is rapid and does not involve radioactivity. These novel in vitro assays may offer a significant advancement in our future management of DHR in children.
既往报告已证明T细胞增殖和细胞因子释放试验作为药物超敏反应(DHR)中药物因果关系的体外诊断试验的效用。然而,与成人数据相比,儿科人群的数据较少。
在儿科人群中比较淋巴细胞增殖试验(LPA)与联合细胞因子试验,并确定其在急性期和恢复后期的潜在用途。
总共进行了18项体外试验,以比较药物特异性增殖和细胞因子释放(干扰素-γ [IFN-γ] 和白细胞介素-4 [IL-4])。该研究纳入了16例DHR患者:7例儿童在急性期进行检测,7例在恢复后进行检测,2例在急性期和恢复后期均进行检测。
儿童DHR急性期LPA的敏感性更高。细胞因子试验显示,在急性期(LPA,77.8%;IFN-γ,88.9%;IL-4,100%)和恢复后期(LPA,33.3%;IFN-γ,66.7%;IL-4,66.7%),与LPA相比,药物特异性阳性反应的频率更高。在急性期和恢复后期,联合细胞因子试验(IFN-γ和IL-4)在识别可疑药物方面产生的药物特异性阳性反应高于LPA。
体外药物诱导的T细胞增殖和细胞因子释放试验有助于识别DHR儿童的致病药物。细胞因子试验(IFN-γ和IL-4)优于LPA,但联合使用时,它们在急性和恢复后DHR的诊断中具有更大的效用。细胞因子检测快速且不涉及放射性。这些新型体外试验可能为我们未来对儿童DHR的管理带来重大进展。